

Theresa L Whiteside

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1108720/theresa-l-whiteside-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

248
papers

17,271
citations

73
h-index

126
g-index

261
ext. papers

20,278
ext. citations

6.4
avg, IF

7.71
L-index

#	Paper	IF	Citations
248	Tumor-Infiltrating Lymphocytes and Their Role in Solid Tumor Progression.. <i>Experientia Supplementum (2012)</i> , 2022 , 113, 89-106	2.2	0
247	NOX activation in reactive astrocytes regulates astrocytic LCN2 expression and neurodegeneration.. <i>Cell Death and Disease</i> , 2022 , 13, 371	9.8	0
246	The Role of Tumor-Derived Exosomes (TEX) in Shaping Anti-Tumor Immune Competence. <i>Cells</i> , 2021 , 10,	7.9	4
245	Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients. <i>British Journal of Cancer</i> , 2021 , 125, 1677-1686	8.7	6
244	DPP4 exosomes in AML patientsQlasma suppress proliferation of hematopoietic progenitor cells. <i>Leukemia</i> , 2021 , 35, 1925-1932	10.7	8
243	IFN γ Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 3661-3673	12.9	2
242	Novel TGF β Inhibitors Ameliorate Oral Squamous Cell Carcinoma Progression and Improve the Antitumor Immune Response of Anti-PD-L1 Immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1102-1111	6.1	2
241	Small Extracellular Vesicles in Pre-Therapy Plasma Predict Clinical Outcome in Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2021 , 13,	6.6	6
240	Tumor-Derived Exosomes (TEX) and Their Role in Immuno-Oncology. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	12
239	Evaluation of Exosome Proteins by on-Bead Flow Cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021 , 99, 372-381	4.6	19
238	The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 241-258	5.4	18
237	Exosomes in Breast Cancer - Mechanisms of Action and Clinical Potential. <i>Molecular Cancer Research</i> , 2021 , 19, 935-945	6.6	5
236	Proteomic profile of melanoma cell-derived small extracellular vesicles in patientsQlasma: a potential correlate of melanoma progression. <i>Journal of Extracellular Vesicles</i> , 2021 , 10, e12063	16.4	12
235	Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression. <i>Melanoma Research</i> , 2021 , 31, 472-475	3.3	2
234	Pneumococcal Extracellular Vesicles Modulate Host Immunity. <i>MBio</i> , 2021 , 12, e0165721	7.8	3
233	Small extracellular vesicle-mediated bidirectional crosstalk between neutrophils and tumor cells. <i>Cytokine and Growth Factor Reviews</i> , 2021 , 61, 16-26	17.9	3
232	Immunoaffinity-Based Isolation of Melanoma Cell-Derived and T Cell-Derived Exosomes from Plasma of Melanoma Patients. <i>Methods in Molecular Biology</i> , 2021 , 2265, 305-321	1.4	6

231	Tumor-derived exosomes promote angiogenesis via adenosine A receptor signaling. <i>Angiogenesis</i> , 2020 , 23, 599-610	10.6	30
230	Molecular profiles and immunomodulatory activities of glioblastoma-derived exosomes. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa056	0.9	16
229	Arginase-1+ Exosomes from Reprogrammed Macrophages Promote Glioblastoma Progression. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	24
228	Purine Metabolites in Tumor-Derived Exosomes May Facilitate Immune Escape of Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	19
227	Transport of Extracellular Vesicles across the Blood-Brain Barrier: Brain Pharmacokinetics and Effects of Inflammation. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	82
226	Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids. <i>Hno</i> , 2020 , 68, 100-105	10.5	10
225	Seroprevalences of autoantibodies and anti-infectious antibodies among Ghanaian healthy population. <i>Scientific Reports</i> , 2020 , 10, 2814	4.9	0
224	CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients' plasma as potential noninvasive biomarkers of disease activity. <i>Oncotmunology</i> , 2020 , 9, 1747732	7.2	23
223	Simultaneous Inhibition of Glycolysis and Oxidative Phosphorylation Triggers a Multi-Fold Increase in Secretion of Exosomes: Possible Role of 2QcAMP. <i>Scientific Reports</i> , 2020 , 10, 6948	4.9	10
222	Role of exosome-associated adenosine in promoting angiogenesis. <i>Vessel Plus</i> , 2020 , 4,	2.3	7
221	Adenosine receptors regulate exosome production. <i>Purinergic Signalling</i> , 2020 , 16, 231-240	3.8	7
220	Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. <i>Scientific Reports</i> , 2020 , 10, 92	4.9	74
219	Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. <i>Transfusion</i> , 2020 , 60, 1867-1872	2.9	
218	Signaling of Tumor-Derived sEV Impacts Melanoma Progression. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	13
217	mRNA and miRNA Profiles of Exosomes from Cultured Tumor Cells Reveal Biomarkers Specific for HPV16-Positive and HPV16-Negative Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
216	Interplay between exosomes and autophagy: Are they partners in crime? 2020 , 197-212		
215	Increased small extracellular vesicle secretion after chemotherapy via upregulation of cholesterol metabolism in acute myeloid leukaemia. <i>Journal of Extracellular Vesicles</i> , 2020 , 9, 1800979	16.4	10
214	Validation of plasma-derived small extracellular vesicles as cancer biomarkers. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 719-720	19.4	6

213	Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. <i>Carcinogenesis</i> , 2020 , 41, 625-633	4.6	31
212	Challenges in Exosome Isolation and Analysis in Health and Disease. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	146
211	Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1133-1141	7.4	5
210	Proteomes of exosomes from HPV(+) or HPV(-) head and neck cancer cells: differential enrichment in immunoregulatory proteins. <i>OncImmunology</i> , 2019 , 8, 1593808	7.2	20
209	Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT. <i>OncImmunology</i> , 2019 , 8, 1593805	7.2	66
208	Optimization of cell culture conditions for exosome isolation using mini-size exclusion chromatography (mini-SEC). <i>Experimental Cell Research</i> , 2019 , 378, 149-157	4.2	41
207	The microbiome in autoimmune diseases. <i>Clinical and Experimental Immunology</i> , 2019 , 195, 74-85	6.2	162
206	Human acute myeloid leukemia blast-derived exosomes in patient-derived xenograft mice mediate immune suppression. <i>Experimental Hematology</i> , 2019 , 76, 60-66.e2	3.1	13
205	Human regulatory T cells (Treg) and their response to cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019 , 4, 215-228	1.6	3
204	Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. <i>Nature Communications</i> , 2019 , 10, 3000	17.4	101
203	Isolation and Analysis of Tumor-Derived Exosomes. <i>Current Protocols in Immunology</i> , 2019 , 127, e91	4	27
202	CD44(+) tumor cells promote early angiogenesis in head and neck squamous cell carcinoma. <i>Cancer Letters</i> , 2019 , 467, 85-95	9.9	22
201	Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	25
200	Bioprinting exosome-like extracellular vesicle microenvironments. <i>Bioprinting</i> , 2019 , 13, e00041	7	15
199	An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. <i>Cancer Cell</i> , 2019 , 35, 33-45.e6	24.3	68
198	Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma. <i>Journal of Extracellular Vesicles</i> , 2018 , 7, 1435138	16.4	132
197	Polyfunctionality of CD4 T lymphocytes is increased after chemoradiotherapy of head and neck squamous cell carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2018 , 194, 392-402	4.3	7
196	Potential roles of tumor-derived exosomes in angiogenesis. <i>Expert Opinion on Therapeutic Targets</i> , 2018 , 22, 409-417	6.4	66

195	Lymphoma exosomes reprogram the bone marrow. <i>Blood</i> , 2018 , 131, 1635-1636	2.2	4
194	Separation of plasma-derived exosomes into CD3 and CD3 fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients. <i>Clinical and Experimental Immunology</i> , 2018 , 192, 271-283	6.2	54
193	Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment. <i>Seminars in Immunology</i> , 2018 , 35, 69-79	10.7	134
192	FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity. <i>Expert Opinion on Therapeutic Targets</i> , 2018 , 22, 353-363	6.4	61
191	Head and Neck Carcinoma Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018 , 24, 6-13	12.9	46
190	Exosomes from HNSCC Promote Angiogenesis through Reprogramming of Endothelial Cells. <i>Molecular Cancer Research</i> , 2018 , 16, 1798-1808	6.6	87
189	IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers. <i>OncoTargets and Therapy</i> , 2018 , 11, 3731-3746	4.4	9
188	Microvessel density in head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018 , 275, 1845-1851	3.5	14
187	Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. <i>Scientific Reports</i> , 2018 , 8, 12905	4.9	88
186	Plasma-derived Exosomes Reverse Epithelial-to-Mesenchymal Transition after Photodynamic Therapy of Patients with Head and Neck Cancer. <i>Oncoscience</i> , 2018 , 5, 75-87	0.8	25
185	Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sjögren syndrome. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 423-434	7.4	14
184	Clinical Significance of PD-L1 Exosomes in Plasma of Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2018 , 24, 896-905	12.9	280
183	The potential of tumor-derived exosomes for noninvasive cancer monitoring: an update. <i>Expert Review of Molecular Diagnostics</i> , 2018 , 18, 1029-1040	3.8	30
182	Harmonization of exosome isolation from culture supernatants for optimized proteomics analysis. <i>PLoS ONE</i> , 2018 , 13, e0205496	3.7	19
181	Molecular and Functional Profiles of Exosomes From HPV(+) and HPV(-) Head and Neck Cancer Cell Lines. <i>Frontiers in Oncology</i> , 2018 , 8, 445	5.3	33
180	Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence. <i>Clinical and Experimental Immunology</i> , 2018 , 194, 67-78	6.2	49
179	Exosomes in acute myeloid leukemia inhibit hematopoiesis. <i>Current Opinion in Hematology</i> , 2018 , 25, 279-284	3.3	22
178	The emerging role of plasma exosomes in diagnosis, prognosis and therapies of patients with cancer. <i>Wspolczesna Onkologia</i> , 2018 , 22, 38-40	1	27

177	Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 4843-4854	12.9	180
176	Targeting adenosine in cancer immunotherapy: a review of recent progress. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 527-535	3.5	52
175	Exosomes carrying immunoinhibitory proteins and their role in cancer. <i>Clinical and Experimental Immunology</i> , 2017 , 189, 259-267	6.2	98
174	The emerging roles of tumor-derived exosomes in hematological malignancies. <i>Leukemia</i> , 2017 , 31, 1259-1268	10.7	116
173	Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia. <i>Scientific Reports</i> , 2017 , 7, 14684	4.9	104
172	Isolation of Exosomes for the Purpose of Protein Cargo Analysis with the Use of Mass Spectrometry. <i>Methods in Molecular Biology</i> , 2017 , 1654, 291-307	1.4	18
171	Stimulatory role of exosomes in the context of therapeutic anti-cancer vaccines. <i>Biotarget</i> , 2017 , 1,	0.7	10
170	Isolation of Biologically Active Exosomes from Plasma of Patients with Cancer. <i>Methods in Molecular Biology</i> , 2017 , 1633, 257-265	1.4	18
169	Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms. <i>Oncolmmunology</i> , 2017 , 6, e1261243	7.2	101
168	The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy. <i>Future Oncology</i> , 2017 , 13, 2583-2592	3.6	75
167	Exosomes in Cancer: Another Mechanism of Tumor-Induced Immune Suppression. <i>Advances in Experimental Medicine and Biology</i> , 2017 , 1036, 81-89	3.6	43
166	The role of tumor-derived exosomes in epithelial mesenchymal transition (EMT). <i>Translational Cancer Research</i> , 2017 , 6, S90-S92	0.3	11
165	Therapeutic targeting of oncogenic KRAS in pancreatic cancer by engineered exosomes. <i>Translational Cancer Research</i> , 2017 , 6, S1406-S1408	0.3	3
164	Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. <i>Journal of Neuro-Oncology</i> , 2016 , 130, 517-527	4.8	36
163	Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. <i>Head and Neck</i> , 2016 , 38, 1008-16	4.2	13
162	Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 811-26	3.8	29
161	Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer 2016 , 4, 24		15
160	Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E494-501	4.2	10

159	Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. <i>Journal of Infectious Diseases</i> , 2016 , 213, 1400-9	7	34
158	Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 1157-68	1	53
157	Phenotypic and functional characteristics of CD39 human regulatory B cells (Breg). <i>OncolImmunology</i> , 2016 , 5, e1082703	7.2	67
156	Circulating Exosomes Carrying an Immunosuppressive Cargo Interfere with Adoptive Cell Therapy in Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 1609-1609	2.2	3
155	Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 1649-1649	2.2	1
154	Tumor-Derived Exosomes and Their Role in Tumor-Induced Immune Suppression. <i>Vaccines</i> , 2016 , 4,	5.3	43
153	Exosomes and tumor-mediated immune suppression. <i>Journal of Clinical Investigation</i> , 2016 , 126, 1216-23	15.9	313
152	Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. <i>Scientific Reports</i> , 2016 , 6, 20254	4.9	212
151	Isolation of biologically active and morphologically intact exosomes from plasma of patients with cancer. <i>Journal of Extracellular Vesicles</i> , 2016 , 5, 29289	16.4	176
150	Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells. <i>Cancer Immunology Research</i> , 2016 , 4, 354-65	12.5	61
149	Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: are we ready?. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 623-9	3.8	28
148	Tumor-Derived Exosomes and Their Role in Cancer Progression. <i>Advances in Clinical Chemistry</i> , 2016 , 74, 103-41	5.8	375
147	Emerging Opportunities and Challenges in Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016 , 22, 1845-55	12.9	172
146	Expression of Submaxillary Gland Androgen-regulated Protein 3A (SMR3A) in Adenoid Cystic Carcinoma of the Head and Neck. <i>Anticancer Research</i> , 2016 , 36, 611-5	2.3	1
145	The potential of tumor-derived exosomes for noninvasive cancer monitoring. <i>Expert Review of Molecular Diagnostics</i> , 2015 , 15, 1293-310	3.8	92
144	Information transfer by exosomes: A new frontier in hematologic malignancies. <i>Blood Reviews</i> , 2015 , 29, 281-90	11.1	59
143	Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. <i>OncolImmunology</i> , 2015 , 4, e1008347	7.2	80
142	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. <i>Cancer Research</i> , 2015 , 75, 2200-10	10.1	175

141	RE: Effect of Nasopharyngeal Carcinoma-Derived Exosomes on Human Regulatory T Cells. <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv276	9.7	2
140	Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV. <i>Cancer Microenvironment</i> , 2015 , 8, 201-7	6.1	18
139	The role of regulatory T cells in cancer immunology. <i>ImmunoTargets and Therapy</i> , 2015 , 4, 159-71	9	77
138	Consensus nomenclature for CD8 T cell phenotypes in cancer. <i>Onc Immunology</i> , 2015 , 4, e998538	7.2	101
137	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. <i>Cancer Research</i> , 2015 , 75, 2200-2210	10.1	114
136	Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 67-72	7.4	125
135	Induced regulatory T cells in inhibitory microenvironments created by cancer. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1411-25	5.4	61
134	Isolation of biologically-active exosomes from human plasma. <i>Journal of Immunological Methods</i> , 2014 , 411, 55-65	2.5	278
133	Isolation and characterization of CD34+ blast-derived exosomes in acute myeloid leukemia. <i>PLoS ONE</i> , 2014 , 9, e103310	3.7	121
132	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014 , 5, 12472-508	3.3	301
131	Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. <i>Clinical and Experimental Immunology</i> , 2014 , 177, 531-43	6.2	165
130	Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia. <i>Frontiers in Immunology</i> , 2014 , 5, 160	8.4	141
129	Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). <i>Biochemical Society Transactions</i> , 2013 , 41, 245-51	5.1	259
128	Immune responses to cancer: are they potential biomarkers of prognosis?. <i>Frontiers in Oncology</i> , 2013 , 3, 107	5.3	62
127	Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease. <i>Frontiers in Immunology</i> , 2013 , 4, 212	8.4	45
126	Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 6585-96	12.9	72
125	Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. <i>British Journal of Cancer</i> , 2013 , 109, 2629-35	8.7	192
124	Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy. <i>Gynecology & Obstetrics (Sunnyvale, Calif)</i> , 2013 , Suppl 4, 3	0	90

123	What are regulatory T cells (Treg) regulating in cancer and why?. <i>Seminars in Cancer Biology</i> , 2012 , 22, 327-34	12.7	206
122	Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. <i>European Journal of Immunology</i> , 2012 , 42, 1876-85	6.1	83
121	CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4(+) T effector cells in patients with head and neck squamous cell carcinoma. <i>OncImmunology</i> , 2012 , 1, 659-669 ²	7.2	45
120	Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. <i>Haematologica</i> , 2011 , 96, 1302-9	6.6	297
119	Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 495-506	7.4	23
118	Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). <i>PLoS ONE</i> , 2010 , 5, e11469	3.7	304
117	Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. <i>Journal of Biological Chemistry</i> , 2010 , 285, 7176-86	5.4	281
116	Immune responses to malignancies. <i>Journal of Allergy and Clinical Immunology</i> , 2010 , 125, S272-83	11.5	129
115	Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. <i>Journal of Biological Chemistry</i> , 2010 , 285, 27571-80	5.4	126
114	Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). <i>Journal of Molecular Medicine</i> , 2010 , 88, 577-88	5.5	30
113	Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. <i>Journal of Immunology</i> , 2009 , 183, 3720-30	5.3	381
112	Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. <i>Journal of Immunology</i> , 2009 , 182, 1469-80	5.3	142
111	Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. <i>Vaccine Journal</i> , 2009 , 16, 233-40		21
110	Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. <i>Head and Neck</i> , 2009 , 31, 371-80	4.2	73
109	IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. <i>Cell Death and Differentiation</i> , 2009 , 16, 708-18	12.7	56
108	Expression and signaling of Toll-like receptor 4 (TLR4) and MyD88 in ovarian carcinoma cells. <i>Journal of Clinical Oncology</i> , 2009 , 27, e16508-e16508	2.2	2
107	The tumor microenvironment and its role in promoting tumor growth. <i>Oncogene</i> , 2008 , 27, 5904-12	9.2	1343
106	T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. <i>Clinical Cancer Research</i> , 2008 , 14, 3706-15	12.9	125

105	Mechanisms of Suppression Used by Regulatory T Cells in Patients Newly Diagnosed with Acute Myeloid Leukemia. <i>Blood</i> , 2008 , 112, 2938-2938	2.2	3
104	CD8+ T cell Recognition of Polymorphic Wild Type Sequence p536573 Peptides in Squamous Cell Carcinoma of the Head and Neck. <i>FASEB Journal</i> , 2008 , 22, 1079.15	0.9	
103	The role of death receptor ligands in shaping tumor microenvironment. <i>Immunological Investigations</i> , 2007 , 36, 25-46	2.9	39
102	Immune Evaluation of Cancer Vaccines 2007 , 291-307		
101	Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. <i>Head and Neck</i> , 2007 , 29, 163-88	4.2	180
100	Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1429-42	7.4	76
99	A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. <i>Clinical Cancer Research</i> , 2007 , 13, 4345-54	12.9	345
98	The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. <i>Clinical Cancer Research</i> , 2007 , 13, 6301-11	12.9	216
97	Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. <i>Cancer Research</i> , 2007 , 67, 8865-73	10.1	123
96	A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide-pulsed dendritic cells in high risk ovarian cancer patients. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3011-3011	2.2	5
95	Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. <i>Seminars in Cancer Biology</i> , 2006 , 16, 3-15	12.7	336
94	Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 3890-5	12.9	174
93	Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles. <i>Immunologic Research</i> , 2006 , 36, 247-54	4.3	92
92	Lymphocyte homeostasis and the antitumor immune response. <i>Expert Review of Clinical Immunology</i> , 2005 , 1, 369-78	5.1	7
91	Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. <i>Clinical Cancer Research</i> , 2005 , 11, 1010-20	12.9	328
90	Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. <i>Journal of Immunology</i> , 2004 , 173, 1526-34	5.3	77
89	Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer?. <i>Cancer Immunology, Immunotherapy</i> , 2004 , 53, 865-78	7.4	120
88	Autologous Glioma Cell Vaccine Admixed with Interleukin-4 Gene Transfected Fibroblasts in the Treatment of Recurrent Glioblastoma: Preliminary Observations in a Patient with a Favorable Response to Therapy. <i>Journal of Neuro-Oncology</i> , 2003 , 64, 13-20	4.8	9

87	Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multi-peptide vaccine in patients with melanoma. <i>Clinical Cancer Research</i> , 2003 , 9, 641-9	12.9	68
86	T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. <i>Clinical Cancer Research</i> , 2003 , 9, 5113-9	12.9	180
85	Cytokine Assays. <i>BioTechniques</i> , 2002 , 33, S4-S15	2.5	22
84	Tumor-induced death of immune cells: its mechanisms and consequences. <i>Seminars in Cancer Biology</i> , 2002 , 12, 43-50	12.7	116
83	Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. <i>Clinical Cancer Research</i> , 2002 , 8, 2553-62	12.9	246
82	Cytokine assays. <i>BioTechniques</i> , 2002 , Suppl, 4-8, 10, 12-5	2.5	5
81	Immunobiology and immunotherapy of head and neck cancer. <i>Current Oncology Reports</i> , 2001 , 3, 46-55	6.3	25
80	The number of intratumoral dendritic cells and E α chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. <i>Cancer</i> , 2001 , 91, 2136-2147	6.4	130
79	Isolation of human NK cells and generation of LAK activity. <i>Current Protocols in Immunology</i> , 2001 , Chapter 7, Unit 7.7	4	3
78	Measurement of cytotoxic activity of NK/LAK cells. <i>Current Protocols in Immunology</i> , 2001 , Chapter 7, Unit 7.18	4	11
77	The number of intratumoral dendritic cells and E α chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma 2001 , 91, 2136		1
76	Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex. <i>Cytometry</i> , 2000 , 41, 321-328		43
75	Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression. <i>Oncogene</i> , 2000 , 19, 514-25	9.2	28
74	Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. <i>Immunological Investigations</i> , 2000 , 29, 121-5	2.9	56
73	Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders. <i>Clinical Transplantation</i> , 1999 , 13, 39-44	3.8	33
72	Ionizing radiation stimulates octamer factor DNA binding activity in human carcinoma cells. <i>Molecular and Cellular Biochemistry</i> , 1999 , 199, 209-15	4.2	28
71	Signaling defects in T lymphocytes of patients with malignancy. <i>Cancer Immunology, Immunotherapy</i> , 1999 , 48, 346-52	7.4	136
70	Immunotherapy with effector cells and IL-2 of lymph node metastases of human squamous-cell carcinoma of the head and neck established in nude mice. <i>International Journal of Cancer</i> , 1999 , 82, 532-7	7.5	16

69	Suppression of cytokine-mediated beta2-integrin activation on circulating neutrophils in critically ill patients. <i>Journal of Leukocyte Biology</i> , 1999 , 66, 83-9	6.5	32
68	Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. <i>Cancer Research</i> , 1999 , 59, 5356-64	10.1	150
67	Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells. <i>European Journal of Immunology</i> , 1998 , 28, 780-6	6.1	47
66	The role of Fas/FasL in immunosuppression induced by human tumors. <i>Cancer Immunology, Immunotherapy</i> , 1998 , 46, 175-84	7.4	92
65	Ionizing radiation and TNF-alpha and stimulated expression of alpha1-antichymotrypsin gene in human squamous carcinoma cells. <i>Acta Oncologica</i> , 1998 , 37, 475-8	3.2	9
64	Natural killer cells and tumor therapy. <i>Current Topics in Microbiology and Immunology</i> , 1998 , 230, 221-44	3.3	91
63	Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo. <i>Clinical Cancer Research</i> , 1998 , 4, 1135-45	12.9	24
62	Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects. <i>Advances in Experimental Medicine and Biology</i> , 1998 , 451, 167-71	3.6	21
61	Ionizing radiation and TNF-a stimulate gene expression of a Thr/Tyr -protein phosphatase HVH1 and inhibitory factor IkbA in human squamous carcinoma cells. <i>Molecular and Cellular Biochemistry</i> , 1997 , 173, 197-201	4.2	2
60	Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma. <i>Cancer Immunology, Immunotherapy</i> , 1997 , 44, 137-49	7.4	15
59	Correlation of constitutive activation of raf-1 with morphological transformation and abrogation of tyrosine phosphorylation of distinct sets of proteins in human squamous carcinoma cells 1997 , 18, 1-6		6
58	Human gastric carcinoma transduced with the IL-2 gene: increased sensitivity to immune effector cells in vitro and in vivo. <i>International Journal of Cancer</i> , 1997 , 72, 174-83	7.5	10
57	Correlation of constitutive activation of raf-1 with morphological transformation and abrogation of tyrosine phosphorylation of distinct sets of proteins in human squamous carcinoma cells 1997 , 18, 1		1
56	Identification and partial purification of a human natural killer cell proliferation-inducing factor. <i>Journal of Biosciences</i> , 1996 , 21, 455-469	2.3	2
55	Partial purification and characterization of a novel human factor that augments the expression of class I MHC antigens on tumour cells. <i>Journal of Biosciences</i> , 1996 , 21, 13-25	2.3	3
54	Divergent effects of Fc gamma RIIIA ligands on the functional activities of human natural killer cells in vitro. <i>European Journal of Immunology</i> , 1996 , 26, 1199-203	6.1	24
53	Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. <i>International Journal of Cancer</i> , 1996 , 68, 276-84	7.5	70
52	Activation of Raf by ionizing radiation. <i>Nature</i> , 1996 , 382, 813-6	50.4	152

51	Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. <i>Human Gene Therapy</i> , 1996 , 7, 1261-80	4.8	217
50	Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma 1996 , 68, 276		1
49	Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer. <i>Anticancer Research</i> , 1996 , 16, 2357-64	2.3	12
48	The Role of Immune Effector Cells in Immunotherapy of Head and Neck Cancer.. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 1995 , 46, 71-83	0	
47	HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck. <i>International Journal of Cancer</i> , 1994 , 57, 297-305	7.5	21
46	Sensorineural hearing loss from quinolinic acid: a neurotoxin in middle ear effusions. <i>Laryngoscope</i> , 1994 , 104, 176-81	3.6	9
45	Comparison of in vivo and in vitro prostaglandin E2 production by squamous cell carcinoma of the head and neck. <i>Otolaryngology - Head and Neck Surgery</i> , 1994 , 111, 189-96	5.5	13
44	Human Natural Killer Cells in Health and Disease. <i>BioDrugs</i> , 1994 , 1, 56-66		12
43	Adoptive Immunotherapy of Cancer. <i>BioDrugs</i> , 1994 , 2, 13-22		3
42	Cytokines and cytokine measurements in a clinical laboratory. <i>Vaccine Journal</i> , 1994 , 1, 257-60		29
41	Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use 1994 , 39, 15		4
40	Abnormalities in the p53 gene in tumors and cell lines of human squamous-cell carcinomas of the head and neck. <i>International Journal of Cancer</i> , 1993 , 54, 322-7	7.5	27
39	Usage of T-cell receptor V beta chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma. <i>International Journal of Cancer</i> , 1993 , 54, 383-90	7.5	34
38	Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. <i>Cancer Research</i> , 1993 , 53, 5654-62	10.1	68
37	Generation and characterization of ex vivo propagated autologous CD8+ cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus. <i>Blood</i> , 1993 , 81, 2085-92	2.2	9
36	Interleukin 2 receptors on squamous cell carcinomas of the head and neck. Characterization and functional role. <i>Acta Oto-Laryngologica</i> , 1992 , 112, 370-5	1.6	10
35	Lymphokine-activated killer cell and natural killer cell activities in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1992 , 35, 694-9		18
34	Phenotypic and functional characteristics of lymphocytes isolated from liver biopsy specimens from patients with active liver disease. <i>Hepatology</i> , 1992 , 15, 816-23	11.2	57

33	Extravasation of antitumor effector cells. <i>Invasion & Metastasis</i> , 1992 , 12, 128-46		15
32	Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 1991 , 13, 15-21	4.2	31
31	Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors. <i>Cancer Immunology, Immunotherapy</i> , 1991 , 32, 280-8	7.4	38
30	Cancer therapy with tumor-infiltrating lymphocytes: evaluation of potential and limitations. <i>In Vivo</i> , 1991 , 5, 553-9	2.3	5
29	Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. <i>Transplantation Proceedings</i> , 1991 , 23, 3047-51	7.1	5
28	Chromosomal breakpoints in cholangiocarcinoma cell lines. <i>Genes Chromosomes and Cancer</i> , 1990 , 2, 300-10	5	48
27	Clonal analysis of tumor-infiltrating lymphocytes from human primary and metastatic liver tumors. <i>International Journal of Cancer</i> , 1990 , 46, 878-83	7.5	38
26	Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. <i>Journal of Clinical Laboratory Analysis</i> , 1990 , 4, 102-14	3	149
25	The biology of human natural killer cells. <i>Annali Dell'istituto Superiore Di Sanita</i> , 1990 , 26, 335-48	1.6	7
24	Serum and tissue banks for biological markers. <i>Immunology Series</i> , 1990 , 53, 55-68		
23	Lymphokine-activated killer cell activity in patients with primary and metastatic malignant liver tumors. <i>Hepatology</i> , 1989 , 10, 221-7	11.2	7
22	Tumor-infiltrating lymphocytes from human solid tumors: antigen-specific killer T lymphocytes of activated natural killer lymphocytes. <i>Immunology Series</i> , 1989 , 48, 139-57		2
21	Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. <i>Cancer Research</i> , 1989 , 49, 5167-75	10.1	177
20	Heterogeneous synthetic phenotype of cloned scleroderma fibroblasts may be due to aberrant regulation in the synthesis of connective tissues. <i>Arthritis and Rheumatism</i> , 1988 , 31, 1221-9		32
19	Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2. <i>Cancer Immunology, Immunotherapy</i> , 1988 , 26, 1-10	7.4	54
18	Characterization of novel anti-tumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes. <i>Transplantation Proceedings</i> , 1988 , 20, 347-50	1.1	8
17	In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors. <i>Cancer Research</i> , 1988 , 48, 6069-75	10.1	21
16	Cloning and proliferating precursor frequencies of tumor-infiltrating lymphocytes from human solid tumors. <i>Transplantation Proceedings</i> , 1988 , 20, 342-3	1.1	14

15	Analysis of intestinal lymphocyte subpopulations in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. <i>American Journal of Clinical Pathology</i> , 1987 , 87, 356-64	1.9	63
14	Expansion of tumor-infiltrating lymphocytes from human solid tumors in interleukin-2. <i>Progress in Clinical and Biological Research</i> , 1987 , 244, 213-22		1
13	Persistence of scleroderma-like phenotype in normal fibroblasts after prolonged exposure to soluble mediators from mononuclear cells. <i>Arthritis and Rheumatism</i> , 1986 , 29, 54-64		35
12	Production of a glycosaminoglycan stimulatory factor by cloned human T lymphocytes activated in vitro. <i>Arthritis and Rheumatism</i> , 1986 , 29, 1071-7		6
11	Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. <i>International Journal of Cancer</i> , 1986 , 37, 803-11	7.5	121
10	Soluble mediators from mononuclear cells increase the synthesis of glycosaminoglycan by dermal fibroblast cultures derived from normal subjects and progressive systemic sclerosis patients. <i>Arthritis and Rheumatism</i> , 1985 , 28, 188-97		56
9	Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. <i>Arthritis and Rheumatism</i> , 1984 , 27, 645-53		323
8	Clinical and serologic study of Sjögren's syndrome in patients with progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1983 , 26, 500-8		77
7	Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1983 , 26, 841-7		71
6	Imbalance of T-cell subpopulations does not result in defective helper function in chronic lymphocytic leukemia. <i>Cancer</i> , 1981 , 48, 1754-60	6.4	13
5	Discrepancies between in vivo and in vitro responses to Candida antigen in patients with progressive systemic sclerosis (PSS; scleroderma). <i>Journal of Clinical Immunology</i> , 1981 , 1, 250-256	5.7	4
4	Immunodiagnosis of mesothelioma: use of antimesothelial cell serum in an indirect immunofluorescence assay. <i>Cancer</i> , 1979 , 43, 2288-96	6.4	40
3	Immunologic characterization of chronic lymphocytic leukemia cells. <i>Cancer</i> , 1977 , 39, 1109-18	6.4	34
2	Use of antibody to membrane adenosine triphosphatase in the study of bacterial relationships. <i>Journal of Bacteriology</i> , 1971 , 105, 957-67	3.5	27
1	Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines	23-43	3